top of page

Antitumor Activity of Ankaferd Blood Stopper® on MCF-7 Breast Cancer: A Proteomic Approach to Ascertain the Mechanism of the Action

"Method : A proteomic approach was chosen to investigate the alteration of the levels of cancer-related proteins of MCF-7 upon subjection to ABS. The proteins were extracted after the 24 h incubation of the cells with the compound (8 μL/mL) and sorted by 2-DE gel electrophoresis. Subsequently, the proteomic profiles of the samples were compared by image analysis. The proteins which were found to be significantly over- or under-expressed were identified by MALDI-TOF/TOF-MS.
Results: Proteomic studies revealed that ABS caused a deviation in the levels of certain proteins including chaperones, p97, ATP5B, SELENBP1, PDIA6, and RPS10P5. The proteins that were significantly up- or down-regulated were further analyzed by using MALDI-TOF/TOF-MS.
Conclusion ABS was validated to target certain proteins that were aberrantly expressed in breast cancer, especially the ER+ subtype. Thus, it can be concluded that this product may be employed for the treatment of breast cancer given its non-toxic and anti-tumor characteristics."

bottom of page